Survival and predictive factors following ruxolitinib failure/discontinuation
| Reference . | Median OS (95% CI) following ruxolitinib failure, mo . | Factors predicting lower survival . |
|---|---|---|
| Newberry et al. (2017)39 | 14 (10-18) | Platelets <260 at ruxolitinib start Platelets <100 at discontinuation Emergent mutations at discontinuation |
| Kuykendall et al. (2018)40 | 13 | Lack of salvage therapy |
| Mascarenhas et al. (2020)41 | 11.1 (8.4-14.5) | Age >65 years Charlson Comorbidity Index |
| Palandri et al. (2020)42 | 13.2 (8.0-22.7) | Blast phase at failure Hb <100 g/L Peripheral blasts >1% |
| Reference . | Median OS (95% CI) following ruxolitinib failure, mo . | Factors predicting lower survival . |
|---|---|---|
| Newberry et al. (2017)39 | 14 (10-18) | Platelets <260 at ruxolitinib start Platelets <100 at discontinuation Emergent mutations at discontinuation |
| Kuykendall et al. (2018)40 | 13 | Lack of salvage therapy |
| Mascarenhas et al. (2020)41 | 11.1 (8.4-14.5) | Age >65 years Charlson Comorbidity Index |
| Palandri et al. (2020)42 | 13.2 (8.0-22.7) | Blast phase at failure Hb <100 g/L Peripheral blasts >1% |